文献速递药物不良反应与药物警戒特殊人群用药

COVID-19患者中安乃近相关中性粒细胞减少风险可能增加

A possible increased risk of metamizole-associated neutropenia among COVID-19 patients.
PubMed 文献 · Br J Clin Pharmacol · 2021-01-07

本文描述3例COVID-19患者在安乃近治疗期间出现严重中性粒细胞减少,提示该人群中性粒细胞减少风险可能增加。安乃近因罕见中性粒细胞减少甚至粒细胞缺乏症在多国被禁用,而COVID-19发热和弥漫性疼痛症状突出,可能导致安乃近广泛使用。目前尚无COVID-19患者中安乃近安全性的报道。

要点

  • COVID-19患者使用安乃近可能增加严重中性粒细胞减少风险
  • 安乃近因罕见中性粒细胞减少和粒细胞缺乏症在多国被禁用
  • COVID-19发热和疼痛症状突出可能导致安乃近广泛使用

核心结论

  • COVID-19患者中安乃近相关严重中性粒细胞减少风险可能增加。

研究设计与样本

  • 本文描述3例在安乃近治疗期间发生严重中性粒细胞减少的COVID-19患者系列病例。

主要发现

  • 3例COVID-19患者在安乃近治疗期间出现严重中性粒细胞减少。

临床怎么用

  • 临床医生应关注COVID-19患者使用安乃近后中性粒细胞减少的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metamizole is commonly used as analgesic and antipyretic drug. The use of metamizole is prohibited in several countries due to its rare side effect of neutropenia and even agranulocytosis. Among the many symptoms of COVID-19, fever and diffuse pain predominant and therefore it can be assumed that metamizole may be widely used in the current epidemic period. So far, there have been no reports on the safety of metamizole in COVID-19 patients. We describe a series of 3 patients who developed severe neutropenia under metamizole treatment, raising a concern of a possible increased risk of this side effect among COVID-19 patients.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Lerman TT, Sagi M, Shafir Y, et al. A possible increased risk of metamizole-associated neutropenia among COVID-19 patients. Br J Clin Pharmacol. 2021. PMID: 33332642. doi:10.1111/bcp.14703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。